OBJECTIVES

: Information regarding chronic obstructive pulmonary disease (COPD)-related healthcare resource utilization (HRU), particularly for moderate/severe patients from low- and middle-income countries, is limited. Here we describe HRU outcomes for patients in Chile enrolled in IMPACT.

METHODS

: IMPACT (NCT02164513), a 52-week, phase III, global randomized controlled trial (N=10,355), evaluated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25µg versus FF/VI 100/25µg or UMEC/VI 62.5/25µg in patients with symptomatic COPD and at least one exacerbation in the previous year. We describe demographics, clinical characteristics and HRU at baseline and during follow-up for patients in Chile. Average HRU per patient and estimated HRU annual rates are described here for outpatient, inpatient, and emergency room visits.

RESULTS

: IMPACT enrolled 371 patients in Chile, with similar demographics and clinical characteristics to the intent-to-treat (ITT) population, but with a higher baseline use of combination treatment with inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA, 61% versus 32% [a post-hoc analysis]). Compared with the ITT population, fewer patients in Chile had severe exacerbations within the year prior to screening (16% versus 26% had 1 exacerbation; 1% versus 4% had ≥2 exacerbations), and a slightly higher proportion of moderate exacerbations (50% versus 47% had ≥2 moderate exacerbations). Overall, distributions were similar between arms.

FF/UMEC/VI reduced on-treatment moderate/severe exacerbations versus FF/VI or UMEC/VI in both Chile (47%, 55%, and 53%, respectively) and the ITT population (47%, 49%, and 50%, respectively). In Chile, on-treatment HRU per patient per year, for office visits (0.64; 0.89; 0.71), emergency room visits (0.15; 0.19; 0.40), and mean number of days in the intensive care unit (0.07; 0.16; 0.15) was lowest with FF/UMEC/VI compared to FF/VI and UMEC/VI, respectively.

CONCLUSIONS

: On-treatment exposure-adjusted exacerbation rates were lower with FF/UMEC/VI compared with the dual therapies in both the Chilean and ITT populations. Similarly, COPD-related HRU was lower with FF/UMEC/VI compared with the dual therapies for both populations.